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Abstract: Anemia is common in patients with chronic heart failure (HF) with an incidence 
ranging from 4% to 55% depending on the studied population. Several studies have high-
lighted that the prevalence of anemia increases with worsening heart failure as reflected by 
New York Heart Association classification. Additionally, several epidemiological studies have 
highlighted its role as a prognostic marker, linking it to worse outcomes including; malnutrition, 
increased hospitalizations, refractory heart failure and death. The pathophysiology of anemia is 
multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet 
drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated 
renal insufficiency. There are a host of epidemiological studies examining HF outcomes and 
anemia, but only a few randomized trials addressing this issue. The purpose of this article is to 
review the literature that examines the interrelationship of anemia and congestive HF, analyzing 
its etiology, impact on outcomes and also the role of associated kidney disease as well as cardio-
renal syndrome both as a marker of morbidity and mortality.
Keywords: anemia, cardio-renal syndrome, heart failure
Background
In the US, heart failure (HF) is a leading cause of hospitalization with an estimated 
number of 900,000 hospitalizations per annum when HF is the primary diagnosis and 
2.6 million when HF is the primary or secondary diagnosis.1 It is estimated that among 
these individuals, 4% to 61% have anemia and up to 33% have chronic kidney disease 
(CKD).2–9 Variability in the estimated prevalence of anemia is partly attributable to use 
of different definitions of anemia in individual reports. Most of these patients are over 
65 years of age, Medicare eligible, and place a huge economic burden on the health care 
system, with an estimated annual cost in the US of approximately $40 billion.10,11
The annual mortality rate of patients suffering from congestive heart failure (CHF) 
refractory to standard medical treatment exceeds 50%.12 Furthermore, deaths attributed 
to HF have increased 145% in the last 2 decades.13 This increased mortality, despite 
advances in medical treatment, points to the importance of identifying factors related 
to poor outcomes and developing new treatment and prevention modalities.
Coronary artery disease (CAD) and hypertension are the two major risk factors for 
the development of HF in older persons. Other common etiologies include diabetes 
mellitus, valvular heart disease – especially aortic stenosis and mitral regurgitation – and 
nonischemic cardiomyopathies. Frequently, HF in older persons is multifactorial.14
Older patients with hypertension and echocardiographic left ventricular (LV) 
hypertrophy had a 2.6-times higher incidence of HF than those with hypertension and Vascular Health and Risk Management 2010:6 238
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no LV hypertrophy. LV hypertrophy by electrocardiography 
(ECG) and diabetes mellitus are also risk factors for the 
development of HF in older persons.14,15 In a 43-month follow 
up of 2902 patients (926 men and 1976 women) with a mean 
age of 81 years, HF developed in 27% of patients. Significant 
independent risk factors for the development of HF were male 
gender (risk ratio = 1.4), hypertension (risk ratio = 2.5), CAD 
(risk ratio = 4.0), diabetes mellitus (risk ratio = 1.6), and age 
(risk ratio = 1.05 for each yearly increase in age).14,16
Anemia, HF and kidney function
In a meta-analysis of 16 studies, Smith et al2 found that 63% 
of 80,098 patients with HF had some degree of concomitant 
impaired renal function, and 29% had severe CKD. This 
is of great clinical relevance because it is well known that 
renal dysfunction in patients with HF is associated with an 
increased risk of adverse outcomes.2,17
In a study by Hillege et al impaired renal function was 
found to be an even stronger predictor of mortality than ejec-
tion fraction (EF) or New York Heart Association (NYHA) 
functional class in 1906 patients with HF.9 The reciprocal 
relationship also holds true and has been the subject of 
much interest. Cardiovascular disease (CVD) is a very 
common comorbidity in patients with CKD or end stage 
renal disease (ESRD)and is the leading cause of mortality 
in this patient population. Indeed, HF is the key component 
of cardiovascular (CV) morbidity and mortality across the 
entire spectrum of CKD, with a 2-year cumulative probability 
of 39.5%.18 In a study of the Medicare population, Foley 
et al found that 39.9% of patients with CKD also had HF 
on initial presentation, and another 30.7% developed it over 
the following year.19 Not only is HF the most common type 
of CV disease seen in patients new to ESRD, but according 
to the US Renal Data System 2007 annual data report, 
approximately two-thirds of incident dialysis patients develop 
HF within 3 years.18
Not surprisingly, CVD is the leading cause of morbidity 
and mortality in dialysis patients, afflicting more than 50% 
of this population. As much as 64% of the ESRD population, 
who are dialysis dependent, have chronic HF, further high-
lighting the bidirectional relationship of these organs.
Most studies indicate that the prevalence of anemia is 
increased in patients with HF who also have co-morbid 
kidney disease, advanced age, and more severe symptoms 
(range, 30% to 61%) when compared with less symptomatic 
ambulatory populations (range, 4% to 23%). In patients with 
HF and preserved ejection fraction, the few published reports 
indicate that anemia is also highly prevalent in this group.20–22 
CKD and HF share a number of causes (eg, hypertension), 
features (eg, malnutrition), and risk factors (eg, older age). 
The relative risk of death in patients diagnosed with HF after 
2 years was increased by a factor of 1.6 in anemic patients 
with heart failure who also had CKD in a large Medicare 
database.23
In patients with HF, acute cardio-renal syndrome 
(CRS) is used to describe an acute decline in kidney 
function associated with decompensated HF. It is present in 
approximately 30% of patients with decompensated HF, the 
frequency varying according to the studied population.24–27 
In more chronic forms of CRS, it may be difficult to deter-
mine what fraction of the heart or kidney dysfunction is the 
result of underlying primary structural disease as apposed 
to a functional decrease, due to dysfunction of the “other” 
organ. Whether acute or chronic, due initially to intrinsic 
heart or kidney disease, anemia is also associated with CRS 
and is a key factor in the pathophysiology contributing to 
morbidity and mortality (see Figure 1). Anemia is thought 
to be related to a combination of factors including chronic 
renal failure, bone marrow suppression through cytokine 
mediated mechanisms, hemodilution and medications such 
as angiotensin converting enzyme (ACE) inhibitors and 
aspirin.28–36
Anemia and cardiovascular disease
The World Health Organization defines anemia as a hemo-
globin count less than 13 g/dL in men and 12 g/dL in 
women.37 If this definition were to be used, anemia is com-
mon in patients with HF.6 Additionally, anemia is common 
in patients with a glomerular filtration rate (GFR) of less than 
60 mL/min, with increasing prevalence noted with declining 
GFR (see Figure 2).6,38
As stated previously, CVD is widely prevalent in patients 
with CKD and more so in dialysis populations. Over half 
of the patients who are end stage renal disease-dialysis 
dependent (ESRD-DD) will die of CVD and its sequelae. 
Parfrey et al reported that around 74% patients have left 
ventricular hypertrophy (LVH), 32% left ventricular 
dilatation and 15% systolic dysfunction on initiation of 
renal replacement therapy (RRT).34 In those on RRT, the 
incidence of de novo ischemic heart disease is 5% and of HF 
11% per year of RRT.36 Of key importance is the finding that 
having both HF and LVH predicts poorer survival in these 
patient populations.34–36 Levin et al looked at pre-dialysis 
CKD populations and noted that both hemoglobin levels and 
systolic blood pressure were associated with LVH. Interest-
ingly, Levin et al also showed that the presence of anemia Vascular Health and Risk Management 2010:6 239
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Figure 1 Schematic diagram showing how anemia causes fluid retention and heart failure which in turn reduced renal perfusion and produces renal dysfunction. Based on 
studies.58,63,88,89,100,101
Abbreviations: BUN, blood urea nitrogen; CHF, congestive heart failure; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy.
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Figure 2 Relationships of the frequency and severity of anemia in a chronic kidney disease population. As renal function worsens, the fraction of subjects with 
hematocrit 33% increases 3-fold, from 24% to 74%.  Drawn from data of Kazmi et al.38Vascular Health and Risk Management 2010:6 240
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and CVD was associated with a reduced time needed for 
the initiation of dialysis.39–41 The impact of anemia, CKD, 
and HF on mortality was assessed in a Medicare sample 
population as shown in Figure 3.42 The presence of CKD 
or HF increased the likelihood of death 2- to 2.5-fold over 
having neither. Anemia increased the likelihood of death to 
almost 4 with either covariate. Having all three increased the 
likelihood of death 6-fold.
Pathophysiology of anemia  
in chronic heart failure
The etiology and pathophysiology of anemia in HF is muti-
factorial. Androne et al reviewed 196 advanced heart failure 
patients and reported that in a subset of 37 ambulatory HF 
patients with anemia, 46% experienced anemia from hemo-
dilution due to expansion of plasma volume rather than a true 
reduction in red blood cell mass, with only 54% experiencing 
“true anemia”.4 Other mechanisms of anemia are associated 
with chronic disease, iron losses due to anti-platelet drugs 
and anticoagulants as well as urinary losses of serum eryth-
ropoeitin (EPO) and transferrin.43,44
HF itself can be considered to produce an inflammatory 
milieu, in which inflammatory cytokines such as interleukins 
1, 6, 18 and tumor necrosis factor alpha (TNF-α) are noted 
to be elevated. Higher levels of TNF-α are found in the 
circulation and in the myocardium of patients with chronic 
heart failure as compared to controls. TNF-α has been impli-
cated in a number of pathophysiological processes that are 
thought to be important in the progression of chronic heart 
failure.45 Patients with NYHA class IV symptoms, those with 
cardiac cachexia and those with edematous decompensation 
of their disease have the highest serum TNF-α levels.46 These 
inflammatory cytokines have been reported to cause anemia 
in vitro.47 Cytokine-mediated responses include reduced red 
blood cell progenitor proliferation, with erythropoietin blunt-
ing, hepcidin elevation with resultant stunted iron absorption 
at the level of the intestine and the blockade of iron release 
from macrophages.48,49 These inhibitory effects of TNF alpha 
are shown schematically in Figure 4.
Both ACE inhibitors and long-term aspirin use have also 
been implicated in the anemia related to HF. The SOLVD 
trial showed a significantly higher prevalence of anemia in 
the Enalapril arm compared with placebo (11.3% vs 7.9%, 
OR 1.56). The authors hypothesized that ACE inhibi-
tors inhibit erythroid precursor cells.50 Angiotensin II is a 
growth factor and ACE inhibitors lead to the formation of 
a tetrapeptide (N-acetyl-seryl-lysyl-proline or AcsSDKP) 
which is an endogenous inhibitor of erythropoiesis.51 This 
property of ACE inhibitors to inhibit erythrocytosis is used 
therapeutically in polycythemic patients and in the setting 
1.0
1.5
2.0 2.0
2.4 2.4
2.9
3.6 3.7 3.7 4.0
4.6 4.7
6.0
6.3
7.3
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
None
DM only
Anemia only
CKD only
DM/CKD only
DM/Anemia only
CHF only
DM/CKD/Anemia only
DM/CHF only
CKD/Anemia only
CHF/Anemia only
DM/CHF/Anemia only
CHF/CKD only
CHF/CKD/Anemia only
DM/CHF/CKD only
DM/CHF/CKD/Anemia
Figure 3 Likelihood for death before end stage renal disease during 2-year of follow-up in Medicare 5% sample: 1996–1997, aged 65 on 1/1/96. Odds ratios adjusted for age, 
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of post transplant erythrocytosis. Anemia from long term 
Aspirin use is thought to be related to masked gastrointestinal 
blood losses. Other contributing factors in the pathogenesis 
of anemia include phlebotomy, the induction of a ferropenic 
state and EPO resistance which is thought to increase with 
HF severity.
Serum erythropoeitin levels and HF
EPO levels have been shown to be elevated in HF. Volpe 
et al noted that plasma EPO levels increased with worsening 
NYHA classification, the exact significance of this finding is 
not fully understood but could be a physiological response to 
increasing anemia as HF worsened.52 In a Netherlands study, 
Van der Meer and colleagues retrospectively examined 74 
Caucasian patients with mild to advanced HF. During the 
mean follow up of 3 years they found that anemia was pres-
ent in 24% of patients, and that increased plasma EPO levels 
were associated with increased mortality, independent of 
hemoglobin levels. Interestingly, they also noted that in HF 
patients, EPO levels did not correlate with the hemoglobin 
levels.53 This lack of a quantitative relationship in the degree 
of anemia, as reflected by hemoglobin and EPO levels in 
HF, is paralleled by a similar observation in patients with 
varying stages of CKD.54 Evidently the effect of circulating 
inflammatory cytokines at multiple sites, including EPO 
production as well as the erythropoietic action of EPO in 
the bone marrow, interferes with the normal operation of the 
feedback system so that it produces an inverse relationship 
of hemoglobin to EPO levels.
The spectrum of cardio-renal 
syndrome
The generic definition of CRS is used to describe an acute 
decline in kidney function in patients with decompensated 
heart failure. The pathophysiology in organ discordance is 
still largely poorly understood but is thought to be related 
to a complex interplay between a structurally failing heart, 
sympathetic, neurohumoral and inflammatory mediators 
resulting in renal vasoconstriction with ischemia contribut-
ing in a reduced GFR. However, many have argued that this 
definition is too simplistic, ambiguous and lacked widespread 
uniformity causing confusion.7,24,49,55 Ronco et al argued that 
communication of both organs was indeed “bi-directional”, 
where one organ, whether heart or kidney, could lead to the 
dysfunction of the other. With this thought process in mind, 
Ronco proposed a classification system that would take into 
account the chronology of the initial organ failure and the 
pathophysiological coping communication interplay that 
ensues. Ronco et al classified CRS into 5 subtypes, giving 
CRS some degree of uniformity.25–27
•  CRS type 1 (acute CRS): characterized by a rapid 
worsening of cardiac function, leading to acute kidney 
injury (AKI). This is thought to be the most common type 
with AKI conferring the worst prognosis.
•  CRS type 2 (chronic CRS): characterized by chronic 
abnormalities in cardiac function (eg, chronic congestive 
HF) causing progressive CKD, thus measuring serum 
creatinine in this setting can often be misleading.
•  CRS type 3 (acute renocardiac syndrome): characterized 
by an abrupt and primary worsening of kidney function 
(eg, AKI, ischemia, or glomerulonephritis).
•  CRS type 4 (chronic renocardiac syndrome): character-
ized by a condition of primary CKD (eg, chronic glo-
merular disease).
•  CRS type 5 (secondary CRS): characterized by the pres-
ence of combined cardiac and renal dysfunction due to 
acute or chronic systemic disorders.
The pathophysiology of worsening renal function in CRS 
is depicted in Figure 5.
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Figure 4 The influence of cytokines in the development of anemia in the cardio-
renal anemia syndrome. TNF-α and other cytokines have an inhibitory effect on 
erythropoietin-stimulating agent-dependent erythropoietic processes in the bone 
marrow (ePO resistance), inhibit remobilization for hemoglobin synthesis through 
hepcidin production, and decrease endogenous ePO production in the kidney.    Anemia 
worsens heart failure, decreases renal perfusion, and leads to a circular cycle.
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Why is CRS important?
The Analysis of the Acute Decompensated Heart Failure 
National Registry (ADHERE) was set up in part to address 
this question.56,57 The results showed that the risk of inpatient 
mortality was significantly increased if patients exhibited 
the following: a blood urea nitrogen (BUN) of greater than 
42 mg/dL; serum sodium less than 134 mmol/L, creatinine 
greater than 3.2 mg/dL, an age greater than 78, dyspnea 
at rest, systolic blood pressures less than 115 mmHg and 
diastolic readings less than 55 mmHg (Table 1). The main 
limitation of ADHERE is that the study was retrospective, 
the data observational, and thus the relationships are asso-
ciative and not necessarily causal.56 In 2006, Smith et al 
reviewed and conducted a metanalysis of 16 studies that 
looked at more than 80,000 patients with HF. They found 
after a 1 year follow up mortality was significantly higher 
in patients with moderate to severe renal impairment, 
compared with those with normal kidney function or even 
mild impairment.2 Furthermore, impaired renal function is 
consistently found as an independent predictor for 1 year 
mortality in acute heart failure patients. An elevated BUN 
even without a reduction in GFR was highlighted as a poor 
prognostic marker by Aronson et al, a finding substantiated 
in the ACTIV in CHF study.58,59 This paradoxical finding is 
thought to be secondary to renal hypoperfusion contributing 
to pre-renal azotemia. Silva and colleagues explored this 
further and noted that both an increased serum creatinine and 
a low ejection fraction (EF) were associated with increased 
death, a finding also supported by Dries et al60 In a large scale 
study, Gottlieb et al showed that a serum creatinine increase 
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Figure 5 Pathophysiology of worsening renal function in cardio-renal syndrome.
Reproduced with permission from Horwich TB, Fonarow GC, Hamilton MA, MacLellan wR, Borenstein J.   Anemia is associated with worse symptoms, greater impairment in 
functional capacity and a significant increase in mortality in patients with advanced heart failure.  J Am Coll Cardiol. 2002;39(11):1780–1786.64 Copyright © 2002 elsevier..
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In the SOLVD trial, low hemoglobin was found to be an 
independent predictor of mortality at a mean follow up of 
33 months (see Figure 6), with a higher mortality associated 
with a hematocrit (Hct) of less than 35 (34%) compared with 
Hct greater than 40 (22%).50 Survival rates steadily declined 
with each decrease in hemoglobin deciles, with no evidence 
of a U-shaped relationship.64 Silverberg and colleagues have 
shown repeatedly that the presence of anemia in HF is associ-
ated with increased mortality (see Figure 7).3,28,63
This has been further verified by Kosiborod et al, who 
looked at 2281 patients that were admitted with a diagnosis of 
HF between 1994 and1995. In both adjusted and non adjusted 
analysis, serum Hct remained an independent predictor for 
of 1 year mortality, – with increased mortality in patients 
with Hct  27% compared to those with 42%. They also 
noted that patients with EF  20% had higher mortality at 
one year compared with patients with EF  40% (hazard 
ratio [HR] = 1.50; 95% confidence interval [CI] 1.20 to 1.86; 
P = 0.0001). Not surprisingly, patients with a low hemoglo-
bin had a higher rate of re-admissions, with 2% associated 
increased risk with each 1% drop in Hct (HR 1.02; 95% 
CI 1.01 to 1.03; P = 0.0002).68
In 2002, Horwich and colleagues, evaluated a cohort of 
1061 patients with NYHA class III–IV , with an EF  40%. 
They divided patients into 4 groups: those with a hemo-
globin 12.3 g/dL, hemoglobin 12.3 to 13.6 g/dL, hemoglobin 
13.7 to 14.8 g/dL and with hemoglobin 14.8 g/dL. They 
found that patients in the lower hemoglobin quartiles were 
more likely to have HF class IV (P = 0.0001); increased 
survival was noted in the higher hemoglobin quartile. On 
multivariate analysis they found that hemoglobin acts as an 
independent predictor for 1-year mortality with mortality 
increasing as hemoglobin decreased below 14 g/dL 
(Figure 7).64 Ezekowitz and coworkers simply dichotomized 
12,065 patients with new onset HF into those with or without 
anemia as defined by the lower limits of normal by gender. 
After adjustment for clinical and demographic variables, 
patients with anemia were more likely to be older (odds ratio 
[OR] 1.01 per year) and female (OR 1.2 [95% confidence 
interval 1.1 to 1.3]) and to have a history of chronic renal 
insufficiency (OR = 3.2; 95% CI 2.8 to 3.6]), or hypertension 
(OR 1.3; 95% CI 1.2 to 1.5]). Hazard ratios for mortality, 
adjusting for covariates, were 1.34 (1.24 to 1.46) in anemic 
patients, and 1.36 (1.23 to 1.50) in those patients with anemia 
of chronic disease. An absolute difference of 15 percentage 
points in survival developed within 1 year (75 vs 60%) in 
non-anemic compared anemic patients, a difference main-
tained for the next 4 years (see Figure 8).69 In a retrospective 
Table 1 Predictors of inpatient mortality in patients with decom-
pensated heart failure
Variable  Died  
(n = 2675)
Survived  
(n = 62,505)
OR of death 
(95% CI)
Age  78 vs  78 1.88 (1.74–2.04)
BUN  42 vs  4.2 3.34 (3.08–3.62)
Cr  3.2 vs  3.2 1.99 (1.78–2.24)
SBP  115 vs  115 3.09 (2.85–3.35)
DBP  55 vs  55 2.87 (2.62–3.14)
Sodium  134 vs  134 2.26 (2.08–2.47)
Dyspnea at rest, n (%) 1220 (46%) 21,757 (35%) 1.57 (1.45–f1.70)
From data of Abraham et al.56
Abbreviations: BUN, blood urea nitrogen; CI, confidence interval; Cr, serum creatine; 
OR, odds ratio; DBP, diastolic blood pressure; SBP, systolic blood pressure.
of greater than 0.3 mg/dL from baseline had a specificity of 
81% in predicting inpatient hospital mortality.61
Associations between cardiorenal 
syndrome and anemia
For many years the existence of anemia with CRS was widely 
ignored, but more recently its role as a prognosticator for 
morbidity and mortality has been elucidated. The importance 
of anemia as a risk factor for progressive HF was highlighted 
as far back as 1987 in the Framingham Study.62 Anemia has 
been revisited more recently as an independent predictor 
of mortality, although with inconsistent results. The true 
prevalence of anemia in CRS is variable, depending upon 
the studied population, ranging anywhere from 4% to 55%, 
with increased incidence noted with worsening NYHA 
classification, and approaching 79% in those with NYHA 
class IV .3,28,48,63–65
Anemia as a predictor of morbidity 
and mortality
Anemia has been associated with worsening structural heart 
disease; diastolic dysfunction, LVH, increased left ven-
tricular mass index and higher pulmonary heart pressures. 
Clinically, anemia is associated with worsening symptoms, 
increased diuretic use, medically refractory heart failure and 
reduced mixed venous oxygen saturation, and contributes to 
“cardiac cachexia” and is associated with increased hospi-
talizations66 and re-hospitalizations.67 Small studies, often 
observational have indicated that the presence of and severity 
of anemia can worsen an NYHA classification in those with 
HF. These findings have been championed by Silverberg and 
colleagues. Their observations have prompted more rigorous 
attention to be paid to anemia correction and management. Vascular Health and Risk Management 2010:6 244
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analysis of Studies of LV Dysfunction (SOLVD) database, 
evaluation of the interaction between the level of Hct and the 
level of GFR on all-cause mortality suggests that anemia and 
reduction in kidney function are more than additive as risk 
factors. In fact, the relative risk of death rises with a drop in 
Hct for each level of GFR (see Figure 9).70
In the Outcomes of a Prospective Trial of Intravenous 
Milrinone for Exacerbations of Chronic Heart Failure 
(OPTIME-CHF) study, hemoglobin levels were noted to be 
an independent risk factor for death and re-hospitalization 
with every 1 g/dL drop in hemoglobin.71 Szachniewicz 
and colleagues conducted a prospective study looking at 
176 patients; their primary endpoint was to determine the 
all-cause mortality. They noted, as with other studies, that 
patients with symptomatic HF as evidenced by a worsening 
NYHA classification had lower hemoglobin levels. On 
Kaplan-Meier survival curves they found that the 18-month 
survival in HF patients with anemia was clinically significant 
compared with those with normal hemoglobin levels.72 The 
PRAISE study, was a prospective multi-center study, that eval-
uated in 1130 patients the associations of EF  30%, NYHA 
classification functional class IIIB or IV , and baseline Hct to the 
most important outcome, patient mortality.5 The findings indi-
cated that anemia was an independent predictor for mortality in 
patients with severe HF. Patients with Hct of 25.4% to 37.5%, 
were noted to have worse mortality, and every 1% decrease 
in Hct was associated with a 11% higher risk of mortality.5 
A recent meta-analysis of 34 studies describing HF and anemia 
by Groenveld and others, identified 153,180 HF patients of 
whom 37.2% were anemic (see Figure 10). After a minimal 
follow-up of 6 months, 46.8% of anemic patients had died 
compared with 29.5% of non-anemic patients. Crude mortality 
risk of anemia had an odds ratio of 1.96 (95% CI 1.74 to 2.21; 
P  0.001). Lower baseline hemoglobin values were associ-
ated with increased crude mortality rates (r = –0.396; P  
0.025). Adjusted hazard ratios showed an increased adjusted 
risk for anemia (HR 1.46; 95% CI 1.26 to 1.69; P = 0.001]). 
Subgroup analysis showed no significant difference between 
mortality risk of anemia in diastolic or systolic HF.73
Whether or not the effect of anemia is truly a directly 
independent effect cannot be readily determined by such 
associative studies since both anemia and degree of HF may 
be due to other variables, particularly co-morbid conditions 
which then create pitfalls in interpreting current observational 
studies examining anemia and HF. Many studies have 
postulated a causal relationship between anemia and HF 
without adjusting for other co-morbidities, making data anal-
ysis questionable. To examine for such a possibility, Kalra 
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et al studied 552 patients with new onset HF, although they 
found a significant increase in the incidence of anemia they 
did not find it to be an independent covariate for worsening 
outcomes when they adjusted for other variables, specifically 
co-morbidities.74
Anemia, CKD and HF
Such confounding results are also present in studies of 
HF complicated by the presence of CKD and anemia. 
In a retrospective analysis by McClellan et al who looked at 
755 patients, who were discharged from community hospitals, 
with a diagnosis of heart failure.17 They found that the 1-year 
death rate with patients with and without a diagnosis of CKD 
were 44.9% and 31.4%, respectively (relative risk 1.43; 95% 
CI 1.17 to 1.75). An Hct was recorded for 633 patients, with 
increasing prevalence of anemia with CKD, the anemia being 
of greater severity with worsening GFR. Strikingly, they 
found the one year mortality to be 31.2% in patients with an 
admission Hct of  40% and 50% in those with an admission 
Hct of 30% to 35%. After multivariate analysis they concluded 
that both hematocrit and serum creatinine were independently 
associated with increased mortality. Unfortunately, the inves-
tigators had to use admission Hct which could have been 
confounded by varying degrees of hemodilution.6 Herzog et al 
examined a cohort of 1,136,201 patients using the 5% general 
Medicare data base, who were enrolled in both Medicare 
Part A and Part B. To decipher whether anemia itself was an 
independent risk factor, they applied co-morbidity-adjusted 
relative risks to each disease state. They noted that patients 
with both CKD and HF were 3.3 times more likely to die 
as compared to the reference population, additionally, they 
showed that there was a 4-fold increased probability of death 
if a patient exhibited anemia, CKD and HF. They found that 
both anemia and CKD served as independent mortality risk 
factors in the elderly population (see Figure 3).75 One criticism 
of this large cohort study is that it shows only associations 
between disease states and these correlations should not be 
misinterpreted as “cause and effect.”
Educating care providers
Despite these observations, anemia in both HF and CRS is 
under treated and under recognized. Silverberg et al writing 
in the Dialysis Times, refer to data obtained in the Cleveland 
clinic looking at 2011 ambulatory patients with HF; 
it was estimated that anemia was only recognized in 11.1% 
of patients and that only a disappointing 10% of those 
diagnosed with anemia were treated for their anemia.28 The 
treatment and management of anemia in CRS requires a 
multidisciplinary approach in addition to educating internists, 
cardiologists and hematologists alike. Silverberg et al noted 
an 8-fold increase in anemia referral to nephrologists after 
in hospital meetings with cardiologists, hematologists and 
internists.76
Treatment of anemia  
and correction of cardiac disease
In HF small differences in hemoglobin are associated with 
worse outcomes and symptoms. Correction and management 
of anemia have been shown to improve NYHA classification, 
LVEF, LVH and diuretic response in some small studies. 
Additionally, in some small studies better outcomes and 
reduced rates of re-hospitalization occur after anemia treat-
ment.3,77–80 Yet, anemia treatment and management in HF 
are controversial, partly because anemia is under recognized 
and diagnosed and there in no consensus as when to begin 
therapy or which agents to use. Treatment and management 
has centered on erythropoietin-stimulating agents (ESAs) and 
parenteral iron supplementation. Unfortunately, most stud-
ies are small, non-randomized or blinded, and consequently 
poorly powered, limiting their validity. In a study of 37 
patients with CHF, iron-deficiency anemia was confirmed 
by bone marrow aspiration in 27 patients (73%), 2 patients 
(5.4%) had dilutional anemia, and 1 patient (2.7%) had drug-
induced anemia. No specific cause was identified in 7 patients 
(18.9%) who were considered to have “anemia of chronic 
disease.” Serum ferritin for the iron-deficient patients was 
not a reliable marker of iron deficiency in this population. 
Thus, the authors concluded that in this group of patients, 
iron deficiency was the most common cause of anemia. The 
iron status of patients with end-stage chronic CHF should be 
thoroughly evaluated and corrected before considering any 
other therapeutic interventions.13
Silverberg and colleagues examined the benefits in 
correcting anemia using a combination of intravenous iron (iron 
sucrose) and ESAs in the form of subcutaneous EPO.3 They 
randomized patients with severe HF (NYHA class III–IV) 
with hemoglobin levels of 10 to 11.5 g/dL into 2 groups, 
a control group (no anemia correction, 16 patients) and a 
treatment group (16 patients, receiving EPO and intravenous 
iron to correct hemoglobin 12.5 g/dL). They noted that with 
anemia correction diuretic response, in patient hospital stay, 
EF, serum creatinine and ferritin improved.3 The required 
dose of diuretics targeting the loop of Henle was markedly 
decreased. Although, ESAs have been noted to produce 
worsening hypertension, at least theoretically, this is not a 
finding that was substantiated by the treated arm. In another Vascular Health and Risk Management 2010:6 248
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larger study, Silverberg and colleagues enrolled 126 anemic 
HF patients with NYHA class III–IV, with hemoglobin 
11.5 g/dL. They noted a marked improvement in NYHA 
classification, LVEF and shortness of breath and fatigue as 
measured by a visual analogue scale and a significant reduction 
in the number of hospitalizations after anemia correction.63,81 
Additionally, serum creatinine remained unchanged, and 
NYHA HF staging improved by 1 full grade (see Table 2). 
The effects of ESAs on hypertension were inconsequen-
tial.81 A single-blind, placebo-controlled, randomized trial 
by Mancini et al evaluated the effect of 3 months of ESAs 
(EPO) treatment on the exercise capacity in 26 patients with 
NYHA functional class III–IV . They demonstrated that the 
ESA-treated group had significantly improved their peak 
oxygen consumption.82 Unfortunately, these studies are lim-
ited by their small sample size, with a need for larger studies 
to substantiate their validity and applicability. Van Der Meer 
and colleagues explored this further through a meta-analysis. 
They identified 7 randomized controlled studies with 650 
HF patients of which 363 were treated with ESAs and 297 
with placebo. All patients identified were in NYHA II or III, 
in all but one study patients had Hct of  40%. They found 
that patients treated with ESAs had a 47% reduction in HF 
related hospitalizations. They did not find a difference in 
mortality between the two groups, or any increase in risk 
of hypertension or venous thrombosis in the ESAs treated 
arms,83 but the sample size may have still been too small.83 
Silverberg reported on an analysis of 10 RCTs. These studies 
succeeded in raising mean hemoglobin to 12 to 13 g/dL, 
with no adverse effects and some benefits. The use of ESAs 
with oral or intravenous iron (in controlled and uncontrolled 
studies) has been associated with significant improvements 
in exercise capacity, oxygen utilization, LVEF, LVH and 
dilation, NYHA classification, BNP, renal function, fatigue, 
caloric intake and overall quality of life.84
Although these analyses are thought provoking, there 
is a need for a large powered randomized phase III trial. 
The STAMINA-HeFT study, a double-blind randomized, 
placebo controlled, multi-center trial, was set up to examine 
the effect of an ESA, darbepoetin alpha (DA) treatment on 
exercise tolerance; secondary endpoints included the effects 
of anemia treatment by DA on clinical symptoms and out-
comes. The study duration was 8 months, enrolling a total of 
319 patients: 157 randomized to placebo and 162 to the DA 
arm. At baseline the median hemoglobin was 11.4 g/dL. By 
week 12, the median hemoglobin in the DA-treated group 
had increased by 1.8 g/dL compared to 0.3 g/dL for placebo 
(P  0.0001). Intent to treat analysis showed that DA did 
not significantly improve exercise duration, NYHA class, 
or quality of life score compared with the placebo group. 
A non-significant trend was observed toward a lower risk 
of all-cause mortality or first HF hospitalization in DA 
treated patients compared with placebo (HR 0.68; 95% CI 
0.43, 1.08; P = 0.10).85 Similar findings were noted in a 
separate controlled trial of darbepoetin with 173 patients.86 
It should be noted that in these two studies, no differences 
occurred in mortality or in the incidence of hypertension, 
venous thrombosis, pulmonary embolus, cerebrovascular 
disorder, myocardial infarction or other cardiovascular 
events. Data are awaited from the ongoing Reduction of 
Events with Darbepoetin alfa in Heart Failure (RED-HF) 
study, a double-blind, multi-centered, placebo-controlled trial 
of darbepoetin in anemic HF patients which now includes 
over a thousand patients treated for 6 to 18 months and has 
a hemoglobin target of 13 g/dL.87
The Trial to Reduce Cardiovascular Events with Aranesp 
Therapy (TREAT) is an ongoing randomized, double-blind, 
multicenter trial designed to determine the impact of anemia 
therapy on mortality and CVD in patients with CKD and type 2 
diabetes. The trial enrolled aover 4000 patients, randomized 
to achieve target hemoglobin of 13 g/dL or 9 g/dL with 
DA therapy. Placebo was being given as “salvage” therapy 
for a hemoglobin of  9 g/dL in the low-hemoglobin group. 
The primary outcome is a composite endpoint of death, 
myocardial infarction, acute myocardial ischemia, CHF, and 
stroke. The TREAT trial may provide critical guidance for the 
future management of anemia in this high cardiovascular-risk 
Table 2 Values before and after treatment of anemia in 
126 consecutive HF patients
Before After
Hemoglobin (g/dL) 10.3 ± 1.4 13.1 ± 1.3*
Hematocrit (%) 30.6 ± 4.1 41.8 ± 32.3*
Serum creatinine (mg/dL) 2.4 ± 1.1 2.3 ± 1.2
∆ in GFR (mL/min/month) –0.95 ± 1.19 +0.27 ± 1.39*
NYHA (0–4) 3.8 ± 0.3 2.7 ± 0.6*
ejection fraction 33.2 ± 0.3 39.6 ± 11.1*
Fatigue/SOB index (0–10) 8.9 ± 1.4 2.7 ± 1.9*
Hospitalizations (n) 3.7 ± 3.5 0.2 ± 0.5*
SBP 132 ± 22.2 131.6 ± 27.9
DBP 75.2 ± 11.7 76.2 ± 11.8
From data of Silverberg et al. 2001.81
*At least P  0.05.
Abbreviations: GFR, glomerular filtration rate; NYHA, New  York Heart Association; 
SOB, shortness of breath; DBP, diastolic blood pressure; SBP, systolic blood 
pressure.Vascular Health and Risk Management 2010:6 249
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population and the impact of hemoglobin on development of 
HF and its outcomes.88
What might the mechanisms be for any salutary effect of 
erythropoietin in HF over and above increasing hemoglobin? 
The potentially beneficial effects of EPO in HF include reduced 
apoptosis of myocytes, reduced cardiac fibrosis, and reduced 
secretion of inflammatory mediators, a positive anti-oxidant 
effect, and neovascularization. The last-named effect has been 
demonstrated in a rat model of myocardial infarction.89
During EPO therapy it is important to avoid iron defi-
ciency. Three studies, 2 uncontrolled90,91 and 1 double-blind, 
placebo-controlled study92 have shown improved hemoglobin, 
LVEF, NYHA class, LVH and dilation, reduced heart rate 
and pulmonary artery pressure with iron treatment alone. In 
addition, they demonstrated improved quality of life, exercise 
capacity, renal function, BNP, CRP and hospitalization. The 
higher the dose of intravenous iron given the greater was the 
hemoglobin response. These studies suggest that iron defi-
ciency may also play a key role in the anemia of HF. Large 
controlled studies on this subject are currently in progress.
Is there an optimal hemoglobin 
level?
The only peer-reviewed HF recommendations that refer to 
anemia in HF, as outlined by the Canadian cardiovascular 
society in 2007, suggests treating any correctable causes of 
anemia (iron, vitamin B12, folate). It also states that cur-
rently there are insufficient data on routine use of ESA in 
the treatment of anemia and HF. However, blood transfusions 
and/or ESAs may be considered if the hemoglobin is less 
than 9 g/dL and after correction of known factors (iron defi-
ciency, vitamin B12, folate) for symptomatic HF.93 In routine 
practice, the answer to this question is mostly expert opinion 
based, with many cardiologists advocating a transfusion 
threshold to maintain an Hct of  30%. This recommendation 
has been chiefly espoused by Herbert et al who noted that, in 
elderly patients suffering from acute myocardial infarction 
and angina, who presented on admission a Hct  30%, had 
better survival outcomes at 30 days if they were transfused.94 
On the other hand, blood transfusion in the setting of acute 
coronary syndromes was associated with higher mortality, 
and this relationship persisted after adjustment for other pre-
dictive factors and timing of events in a retrospective cohort 
analysis of prospectively collected clinical trial data.95 In this 
study, the median baseline and nadir Hct measurements for 
patients who received a transfusion were 39.9% and 29.0%, 
respectively, and for patients who did not receive blood, the 
values were 41.7% and 37.6%, respectively.95
In the Normal Hematocrit Treatment trial, Besarab et al 
randomly assigned 1233 hemodialysis patients to Hct targets 
of either 30% or 42%. Unfortunately, the trial was prema-
turely stopped for a statistically significant excess of vascular 
access thrombosis, with a non-significant increase in primary 
end points, namely non-fatal myocardial infarctions and death 
in the 42% Hct group.96 Later came the Open Label Correc-
tion of Hemoglobin and Outcomes in Renal Insufficiency 
(CHOIR) study, which randomly assigned 1432 CKD patients 
to either hemoglobin targets of 11.3 g/dL or higher values of 
13.5 g/dL. There was a significantly higher rate of primary 
outcome events, namely myocardial infarction, stroke, HF 
hospitalization and death in the normal hemoglobin group.97 
Paradoxically a subsequent analysis indicated that it was not 
just the hemoglobin per se, but the inability to respond to 
increasing doses of EPO that predicted worse outcomes.98 
Individuals administered progressively larger doses of ESA 
and those who could not attain the targeted hemoglobin of 
13.3 were the ones at risk for morbidity and mortality. Our 
take home lesson should be that ESA resistance should not 
be treated with increases in ESA alone.
Conclusion
Anemia in the setting of HF is debilitating, fraught with 
severe morbidity and mortality in an ever-aging population. 
Many studies have highlighted the ominous implications of 
leaving this problem unresolved. Just as internists are rec-
ognizing the benefits in improving mortality and morbidity 
in early CKD referral, internists and cardiologists should be 
educated to recognize the hallmark of anemia as its manage-
ment may make a difference in HF outcomes. This underpins 
the need for better system based practices that need to evolve 
beyond pharmacological methods tackling HF and should 
include anemia management.
None of the HF clinical practice guidelines from the US 
or Europe currently discuss the assessment and management 
of anemia in HF. Given current evidence, the use of ESA 
and supplemental iron should only be considered in patients 
with concomitant CKD or in the management of anemia 
(hemoglobin  9 g/dL) with severe symptomatic heart failure, 
after iron, vitamin B12 and folate replacement. The National 
Kidney Foundation KDOQI™ clinical practice guideline 
were updated in 2007 after publication of the CREATE and 
CHOIR trials and recommended the use of ESA to achieve 
a hemoglobin target in the range of only 11.0 to 12.0 g/dL.99 
With the removal of the quality of life claim by the Food and 
Drug Administration, the only claim for the use of ESA is to 
improve quality of life measures such as exercise tolerance Vascular Health and Risk Management 2010:6 250
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and functional ability of CKD patients.100 In HF patients, 
even these quality of life measures have not been convinc-
ingly shown to improve. Therefore, until data from long-term 
clinical studies are available for HF patients with anemia, the 
use of ESA is not recommended in anemic patients with HF 
who do not have a CKD indication for its use.
Anemia is a common co-morbidity in patients with HF 
and is associated with worse long-term outcomes. Although 
the cause of anemia in HF is unclear, the weight of evidence 
suggests that renal dysfunction and neurohormonal and pro-
inflammatory cytokine activation in HF favor the develop-
ment of anemia. Similarly, the mechanisms by which anemia 
worsens HF outcomes are unknown but may be related to 
increased myocardial workload. Although anemia is a ratio-
nal therapeutic target to improve outcomes, there are as yet 
no convincing data on the efficacy and long-term safety of 
ESA. Further studies are required to understand the basis of 
the remarkable association of anemia with HF outcomes, to 
assess prospectively the potential benefit of correcting ane-
mia, to evaluate the ideal threshold at which therapy should 
be initiated, and the extent of correction considered safe and 
desirable. Two large mortality morbidity trials, TREAT in 
CKD88 and RED-HF in HF, are in progress and may be able 
to provide answers to some of these questions.87
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